Gsk Share Discussion Threads

[netcurtains] 01/2/2023 10:02

So far its been 99% of the time blue.

[netcurtains] 01/2/2023 10:00

I think the Zantac news is more or less all out of the way (bulk of cases).
The results were good.

No idea if will rise, we will know at two points: 10:30am
and 3:45pm (in my opinion).

[abdullla] 01/2/2023 09:29

I don't think its going up until the Zantac bad news is out of the way

[tuftymatt] 01/2/2023 08:14

Yeah you never can tell how the market will react to news but I would hope we get a challenge of 1500 going off the back of that 👍🏻

[netcurtains] 01/2/2023 08:08

Early days.
We normally get two patterns reaching decisions.
One about 10am
and another about 3:45pm.

Clearly the results are good.
What the price does is anyone's guess.

[abdullla] 01/2/2023 08:05

Now watch it going down,as always

[spoole5] 01/2/2023 08:04

Market not that impressed, as always!

[netcurtains] 01/2/2023 07:54

Blimey - Great Results.

[turvart] 01/2/2023 07:31

Certainly were cracking results and I feel confident today that we should see a nice rise, I see the ex div date is 23rd Feb and I think 1600p may be visited again going into ex div, as always we will see ;-)

[mj19] 01/2/2023 07:29

Meanwhile, GSK chief executive Emma Walmsley said the drugs giant started 2023 with good momentum after reporting 14% growth in annual operating profits to £8.15 billion.

[coxsmn] 01/2/2023 07:06

Great results

[mj19] 31/1/2023 09:54

Just good for dividend and take over should be good

[tuftymatt] 31/1/2023 08:33

A little brighter here which is good to see.
Can we push and hold 1450 during Feb or will we bounce around 1390 / 1420???

[netcurtains] 30/1/2023 13:05

Rise towards results - better late than never.
But we never know until USA opens...

Cheers Net.

[netcurtains] 26/1/2023 15:50

Thanks TM.

[tradermichael] 26/1/2023 15:41

Its almost a daily event, as soon as Wall Street opens .... ;0)

[grahamburn] 26/1/2023 15:32

A 10p price change on 1400-odd-p is hardly dramatic especially as the price is effectively level on the day so doesn't justify starting yet another rumour.

[netcurtains] 26/1/2023 15:23

Is there any breaking rumour that has caused this to go into the RED?
Its been GREEN all morning.
Any views as to why the change?

[grahamburn] 26/1/2023 14:24

Thank you BD.

I know NC probably cannot see this post (he may well bot have filtered me), but I, like you, I fail to see how quoting/summarising facts from a report can be classified as "agressive".

BBs are for reasoned debate and for exchanging opinions and ideas in a civilised, friendly manner.

NC saying the report is "sanitised" without providing evidence is verging on a rumour. That is potentially misleading.

[tradermichael] 26/1/2023 09:30

Haleon releases its fourth quarter and final year 2022 results on 2nd March. Credit Suisse predict organic sales growth of 3.7% and OTC growth of 5.0%.

On an earnings discount to European rivals, 'outperform' is the investment rating with a share price target of 376p.

[alibizzle] 26/1/2023 09:28

Share price recovering a little

[netcurtains] 26/1/2023 08:02

bothdavis: I did not block him for that. I dont want to discuss it further. Thank you. Its not called debate its called being overly aggressive and self righteous. He had to go. Share investing can get overly emotional and I dont need this agro thrown on top. I personally did not have 4th jab. I'm reasonably glad I did not. Many other people see it differently. I know that. Thank you for not debating this. Ad nauseum

[bothdavis] 25/1/2023 22:25

Why block grahamburn for stating what is in the report?

The review of more than 8,000 reported cases from 46 studies by researchers in Canada confirms previous reports that myocarditis is rare, but cases are highest among young males shortly after a second dose, and are probably higher after Moderna’s mRNA vaccine than after Pfizer’s vaccine.

It also shows that, while cases are predominantly mild, the risk of myocarditis or pericarditis might be lower when the second dose is given more than 30 days after the first dose.

However, the researchers warn that, in general, the evidence is of low certainty and say these findings must be considered alongside the overall benefits of vaccination.

So~: 'confirms previous reports that myocarditis is rare', the evidence is of low certainty and.......findings must be considered alongside the overall benefits of vaccination'

It is called 'debate', and I'm afraid it merely backs up the facts that vaccination is the best thing to have done for the population as a whole.